159 related articles for article (PubMed ID: 38287501)
21. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
22. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
[TBL] [Abstract][Full Text] [Related]
23. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
Çağlayan Ç; Goldstein JS; Ayer T; Rai A; Flowers CR
Cancer; 2019 Jun; 125(11):1837-1847. PubMed ID: 30707765
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
25. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
26. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Laribi K; Denizon N; Bolle D; Truong C; Besançon A; Sandrini J; Anghel A; Farhi J; Ghnaya H; Baugier de Materre A
Ann Hematol; 2016 Oct; 95(10):1705-14. PubMed ID: 27485454
[TBL] [Abstract][Full Text] [Related]
27. Frailty status but not age predicts complications in elderly cancer patients: a follow-up study.
Ørum M; Gregersen M; Jensen K; Meldgaard P; Damsgaard EMS
Acta Oncol; 2018 Nov; 57(11):1458-1466. PubMed ID: 30280625
[TBL] [Abstract][Full Text] [Related]
28. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
29. Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma.
Zhang J; Disperati P; Elinder-Camburn A; Merriman E; Leitch S; Chan H
J Geriatr Oncol; 2022 May; 13(4):505-510. PubMed ID: 34906444
[TBL] [Abstract][Full Text] [Related]
30. Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China.
Zhong YP; Zhang YZ; Liao AJ; Li SX; Tian C; Lu J
Chin Med J (Engl); 2017 Jan; 130(2):130-134. PubMed ID: 28091402
[TBL] [Abstract][Full Text] [Related]
31. Retrospective Analysis of Treatment Outcomes and Geriatric Assessment in Elderly Malignant Lymphoma Patients.
Naito Y; Sasaki H; Takamatsu Y; Kiyomi F; Tamura K
J Clin Exp Hematop; 2016; 56(1):43-9. PubMed ID: 27334857
[TBL] [Abstract][Full Text] [Related]
32. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.
Olivieri A; Gini G; Bocci C; Montanari M; Trappolini S; Olivieri J; Brunori M; Catarini M; Guiducci B; Isidori A; Alesiani F; Giuliodori L; Marcellini M; Visani G; Poloni A; Leoni P
Oncologist; 2012; 17(5):663-72. PubMed ID: 22531362
[TBL] [Abstract][Full Text] [Related]
33. Utility of the Geriatric 8 for the Prediction of Therapy-Related Toxicity in Older Adults with Diffuse Large B-Cell Lymphoma.
Oiwa K; Fujita K; Lee S; Morishita T; Tsukasaki H; Negoro E; Ueda T; Yamauchi T
Oncologist; 2021 Mar; 26(3):215-223. PubMed ID: 33320984
[TBL] [Abstract][Full Text] [Related]
34. Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment.
Yoshida M; Nakao T; Horiuchi M; Ueda H; Hagihara K; Kanashima H; Inoue T; Sakamoto E; Hirai M; Koh H; Nakane T; Hino M; Yamane T
Eur J Haematol; 2016 Apr; 96(4):409-16. PubMed ID: 26084899
[TBL] [Abstract][Full Text] [Related]
35. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Ferrari A; Spina M; Tucci A; Stelitano C; Capodanno I; Fragasso A; Baldini L; Bottelli C; Montechiarello E; Fogazzi S; Lamorgese C; Cavalli L; Federico M;
Leuk Lymphoma; 2014 Jan; 55(1):38-43. PubMed ID: 23517562
[TBL] [Abstract][Full Text] [Related]
36. Curing diffuse large B-cell lymphomas in elderly patients.
Moccia AA; Thieblemont C
Eur J Intern Med; 2018 Dec; 58():14-21. PubMed ID: 30472108
[TBL] [Abstract][Full Text] [Related]
37. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Rev Anticancer Ther; 2022 Jun; 22(6):583-595. PubMed ID: 35472312
[TBL] [Abstract][Full Text] [Related]
38. Curative intent therapy for DLBCL in the elderly.
Tucci A; Masina L; Luminari S
Leuk Lymphoma; 2024 May; 65(5):560-569. PubMed ID: 38206922
[TBL] [Abstract][Full Text] [Related]
39. Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Eyre TA; Martinez-Calle N; Hildyard C; Eyre DW; Plaschkes H; Griffith J; Wolf J; Fields P; Gunawan A; Oliver R; Djebbari F; Booth S; McMillan A; Fox CP; Bishton MJ; Collins GP; Hatton CSR
J Intern Med; 2019 Jun; 285(6):681-692. PubMed ID: 30811713
[TBL] [Abstract][Full Text] [Related]
40. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl A; Cunningham D; Counsell N; Hawkes EA; Qian W; Smith P; Chadwick N; Lawrie A; Mouncey P; Jack A; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Rosenwald A; Ott G; Horn H; Ziepert M; Pfreundschuh M; Linch D
Ann Oncol; 2017 Jul; 28(7):1540-1546. PubMed ID: 28398499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]